Drug Therapy Management, Version 2.0 DTM 23 - Program Evaluation Methodology Disclosure
The Basics
URAC requires that your DTM program's disclosures of program evaluation, required by the previous standards, include these components:
- a description of the program evaluation methodology;
- a description of the strengths and limitations of that methodology; and
- any available external validation of that methodology.
In other words, the standard merely puts meat on the bones of the previous standard, describing what elements should be in the reports you provide to prospective and current purchasers when they request your program evaluation documentation.
Management Tips
The requirements of the standard can be incorporated into the policies and procedures submitted for the previous two standards.
URAC Accreditation Tips
The basic requirement that you describe your program evaluation methodology is mandatory; the other elements (strengths and limitations and external validation) are Leading Indicators, and are therefore optional.
The desktop review submission should include both policy and procedure describing a year staff should handle requests for performance evaluation reports and sample reports provided to current and prospective purchasers.
The on-site reviewer will examine data and information that you provide to purchasers. In addition, he/she will interview staff members to assess their understanding of the process.
